±èÁ¤¾Æ ±³¼ö, ´ç´¢º´°ú Áö¹æ°£ Áúȯ ¿¬±¸·Î ÃÖ¿ì¼ö±¸¿¬»ó ¼ö»ó
°í·Á´ë ¾È¾Ïº´¿ø ³»ºÐºñ³»°ú ±èÁ¤¾Æ ±³¼ö, ±¹Á¦Çмú´ëȸ¼ MASLD¿Í ´ç´¢º´ ¿¬°ü¼º ±Ô¸í ¿¬±¸ ¹ßÇ¥
µî·Ï: 2025.10.02
[¸ÞµðÄÃÅõµ¥ÀÌ=±è¹Ì°æ ±âÀÚ] °í·Á´ëÇб³ ¾È¾Ïº´¿ø ³»ºÐºñ³»°ú ±èÁ¤¾Æ ±³¼ö°¡ Áö³ 9¿ù 25ÀϺÎÅÍ 27ÀϱîÁö ¼¿ï ±×·£µå ¿öÄ¿Èú¿¡¼ ¿¸° ´ëÇÑ´ç´¢º´ÇÐȸ ±¹Á¦Çмú´ëȸ ¡®2025 KDA Scientific Meeting: 15th International Congress of Diabetes and Metabolism (ICDM2025)¡¯¿¡¼ ÃÖ¿ì¼ö±¸¿¬»óÀ» ¼ö»óÇß´Ù.
±è ±³¼ö´Â 'Liver-related complications and mortality in type 1 and type 2 diabetes with metabolic dysfunction associated steatotic liver disease'¶ó´Â Á¦¸ñÀÇ ¿¬±¸ ¹ßÇ¥¸¦ ÅëÇØ ¼ö»óÀÇ ¿µ¿¹¸¦ ¾È¾Ò´Ù.
À̹ø ¿¬±¸´Â ´ë»çÀÌ»óÁö¹æ°£Áúȯ(MASLD)À» µ¿¹ÝÇÑ 1Çü ¹× 2Çü ´ç´¢º´ ȯÀÚ¿¡¼ °£ °ü·Ã ÇÕº´Áõ ¹ß»ý À§ÇèÀÌ Áõ°¡Çϸç, ƯÈ÷ 1Çü ´ç´¢º´ ȯÀÚ¿¡¼ ÀÌ·¯ÇÑ À§Çèµµ°¡ ´õ¿í ³ô´Ù´Â »ç½ÇÀ» ±Ô¸íÇß´Ù. ÀÌ´Â ÇаèÀÇ Å« ÁÖ¸ñÀ» ¹Þ¾Ò´Ù.
±è ±³¼ö´Â ¿¬±¸ °á°ú ¹ßÇ¥ ÈÄ, "À̹ø ¿¬±¸´Â Á¦1Çü ´ç´¢º´ ȯÀÚ¿¡¼ ´ë»çÀÌ»óÁö¹æ°£ÁúȯÀÇ ÀÓ»óÀû À§Ç輺À» ±Ô¸íÇß´Ù´Â Á¡¿¡¼ Å« Àǹ̸¦ °®´Â´Ù"°í ¹àÇû´Ù. ÀÌ¾î ±×´Â "ÇâÈÄ ´ç´¢º´ ȯÀÚ¸¦ ´ë»óÀ¸·Î MASLD¿¡ ´ëÇÑ Àû±ØÀûÀÎ ¼±º°°Ë»ç¿Í ÇÔ²² Ç÷´ç, ´ë»ç ÁöÇ¥, ºñ¸¸¿¡ ´ëÇÑ Á¶±â °ü¸®°¡ ÇÊ¿äÇÏ´Ù"°í °Á¶Çß´Ù.
±è¹Ì°æ
sallykim0113@mdtoday.co.kr
* º» ±â»çÀÇ ³»¿ëÀº ¸ÞµðÄÃÅõµ¥ÀÌ ¾ð·Ð»ç¿¡¼ Á¦°øÇÑ ±â»çÀ̸ç ÇコÁ¶¼±ÀÇ ÆíÁý¹æÇâ°ú ÀÏÄ¡ÇÏÁö ¾ÊÀ» ¼öµµ ÀÖ½À´Ï´Ù.(°ü·Ã ¹®ÀÇ´Â ÇØ´ç ¾ð·Ð»ç¿¡ ¿¬¶ôºÎʵ右´Ï´Ù)